Inventiva S.A. (0RNK.L)
| Previous close | 2.9900 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 1,962 |
| Market cap | 570,342 |
| Beta (5Y monthly) | 0.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2670 |
| Earnings date | 27 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
BenzingaWhy Is Inventiva's Stock Trading Higher on Monday?
Inventiva SA (NASDAQ:IVA) announced the publication in the peer-reviewed scientific journal Nature Communications of additional results from its NATIVE Phase 2b trial demonstrating the improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor. Following lanifibranor treatment, the trial demonstrated significant improvement in patients with metabolic dysfunction-associated steatohepatitis (MASH)/ non-alcoholic steatohepatitis (NASH) with and without Typ
GlobeNewswireInventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor
Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG) levels), systemic inflammation (hs-CRP, ferritin), hepatic steatosis and diastolic blood pressure.Among the patients who had prediabetes at study entry and were treated with lanifibranor, the majority had fasting glucose levels within the normal range at the end of treatment. No patient treated with lanif
Globe NewswireInventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that it had filed its 2023 Universal Registration Docum
